Ureteral Stenting After Retrograde Intrarenal Surgery for Renal Stones

Sponsor
Al-Azhar University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05738304
Collaborator
(none)
250
1
2
34.6
7.2

Study Details

Study Description

Brief Summary

Several studies evaluated the benefit of a short-term external ureteral catheter (UC) compared to double-J (DJ) ureteral stent after flexible ureteroscopy (URS); the results were controversial. These studies had combined analyses of ureteral and renal stones with a high risk of selection bias. Studies comparing external UC and DJ stent after flexible URS for isolated renal stones are lacking.

In the present study, the investigators will compare the outcomes of using a one-day external UC versus a DJ internal ureteral stent for ureteral drainage after retrograde flexible URS (retrograde intrarenal surgery "RIRS") for renal stones. The investigators aim to identify the best ureteral drainage method after RIRS regarding stone clearance, complications, and stent-related symptoms.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Retrograde intrarenal surgery with external ureteral catheter
  • Procedure: Retrograde intrarenal surgery with double J internal ureteral stent
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
250 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
One-Day External Ureteral Catheter Versus Double-J Internal Ureteral Stent After Retrograde Intrarenal Surgery for Renal Stones: A Prospective, Randomized Trial
Actual Study Start Date :
Jan 12, 2021
Anticipated Primary Completion Date :
Nov 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: External Ureteral Catheter group

After RIRS, an external ureteral catheter will be placed for one day.

Procedure: Retrograde intrarenal surgery with external ureteral catheter
The retrograde fURS sheathless technique will be used in all cases, including (a) cystourethroscopy with the introduction of a guidewire into the ipsilateral ureter up to the collecting system; (b) Semi-rigid ureteroscopy (using 9.5 Fr, Karl Storz, semi-rigid ureteroscope) for visualization of the ureter for any abnormalities, the introduction of the second guidewire and hydrophilic ureteral dilation; (c) introduction of the flexible ureteroscope (8.6 Fr, single-use digital flexible ureteroscope, OUT Medical Inc.) over the guidewire up to the kidney; (d) removal of the working guidewire after visualization of the stone; and (e) fragmentation of the stone using a holmium YAG laser device. All procedure steps will be performed under direct visualization and fluoroscopy guidance. At the end of the procedure, an external ureteral catheter will be placed for 24 hours.

Active Comparator: Double J group

After RIRS, a double J internal ureteral stent will be placed for 2 weeks.

Procedure: Retrograde intrarenal surgery with double J internal ureteral stent
The retrograde fURS sheathless technique will be used in all cases, including (a) cystourethroscopy with the introduction of a guidewire into the ipsilateral ureter up to the collecting system; (b) Semi-rigid ureteroscopy (using 9.5 Fr, Karl Storz, semi-rigid ureteroscope) for visualization of the ureter for any abnormalities, the introduction of the second guidewire and hydrophilic ureteral dilation; (c) introduction of the flexible ureteroscope (8.6 Fr, single-use digital flexible ureteroscope, OUT Medical Inc.) over the guidewire up to the kidney; (d) removal of the working guidewire after visualization of the stone; and (e) fragmentation of the stone using a holmium YAG laser device. All procedure steps will be performed under direct visualization and fluoroscopy guidance. At the end of the procedure, a double-J internal ureteric stent will be placed for 2 weeks.

Outcome Measures

Primary Outcome Measures

  1. Stone free rate [up to 1 month]

    No stones or residual fragments >3 mm on postoperative imaging study

  2. Stent-related symptoms [from post operative day one till double J removal; an average of 2 weeks]

    Irritative lower urinary tract symptoms

Secondary Outcome Measures

  1. Postoperative renal pain [up to 1 month]

    Renal pain attacks and severity as evaluated by visual analogue pain scale (VAPS). The VAPS is a pain rating scale based on self-reported measures of symptoms that are recorded with a single handwritten mark placed at one point along the length of a 10-cm line that represents a continuum between the two ends of the scale-"no pain" on the left end (0 cm) of the scale and the "worst pain" on the right end of the scale (10 cm).

  2. Rehospitalization rate [From post RIRS home discharge up to one month]

    the need for unscheduled hospital admission

  3. Reintervention rate [up to 3 months]

    the need for reoperation

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

• Adult patients of either gender in whom RIRS was the primary modality.

Exclusion Criteria:
  • Pregnant women

  • Active urinary tract infection

  • solitary kidney

  • Concomitant pathology that need intervention in the same setting

  • Patients with surgical incidents that indicate double-J stenting (Residual sizable fragments, ureteral false passage, ureteral mucosal laceration, ureteral perforation, and calyceal rupture).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Urology Department, Al-Azhar University Hospital Cairo Egypt

Sponsors and Collaborators

  • Al-Azhar University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Abul-fotouh Ahmed, Professor, Al-Azhar University
ClinicalTrials.gov Identifier:
NCT05738304
Other Study ID Numbers:
  • Uro_Azhar_11_023
First Posted:
Feb 22, 2023
Last Update Posted:
Feb 22, 2023
Last Verified:
Feb 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 22, 2023